Differential metallothionein expression in oral lichen planus and amalgam-associated oral lichenoid lesions

Gabriela-Geraldo Mendes 1, João-Paulo-Silva Servato 2, Fabiana-Custódio Borges 1, Roberta-Rezende Rosa 1, Carla-Silva Siqueira 3, Paulo-Rogério de Faria 4, Adriano-Mota Loyola 1, Sérgio-Vitorino Cardoso 1

1 Oral Pathology Area, School of Dentistry, Federal University of Uberlândia (UFU), Uberlândia, Minas Gerais, Brazil
2 Biopathology Area, School of Dentistry, University of Uberaba (UNIUBE), Uberaba, Minas Gerais, Brazil
3 School of Medicine, Federal University of Goiás (UFG), Jataí, Goiás, Brazil
4 Area of Morphology, Biomedical Sciences Institute, Federal University of Uberlândia (UFU), Uberlândia, Minas Gerais, Brazil

Correspondence:
Universidade Federal de Uberlândia
Faculdade de Odontologia
Área de Patologia. Av. Purã, 1720
Campus Umuarama. CEP: 38405-320
Uberlândia – MG Brazil
sv.cardoso@ufu.br

Received: 25/08/2017
Accepted: 10/04/2018

Abstract
Background: Oral lichen planus (OLP) is a chronic inflammatory disease mediated by T cells, which manifests as reticular (white) or erosive (red) lesions, that are eventually painful. Oral lichenoid lesion (OLL) are distinguished from OLP by the presence of precipitating factors. The aim of this study was to evaluate whether the presence of metallothionein, which is involved in anti-apoptotic pathways and the anti-oxidative response, could serve as a differential diagnostic for OLP and OLL.

Material and Methods: We evaluated the expression of metallothionein in 40 cases of OLP and 20 cases of OLL using immunohistochemistry.

Results and Conclusions: White OLP has higher concentrations of metallothionein than red OLP in basal and parabasal layers. Moreover, metallothionein was more frequently observed in the cytoplasm and nuclei of basal cells in OLP patients compared to the same regions of OLL cases. Metallothionein levels are related to OLP severity and may contribute to a differential diagnosis between OLP and OLL.

Key words: Oral lichen planus, oral lichenoid lesions, autoimmune disorders, metallothionein, immunohistochemistry.
Introduction
Oral lichen planus (OLP) is a chronic autoimmune disease of the oral mucosa, mediated by T lymphocytes (1-4). It is found in up to 2% of adults, more frequently in women, in the fifth to sixth decades of life (1-4). Typically, OLP manifests bilaterally in tongue and/or buccal mucosa, as white striae or plaques with striated borders. Some cases occur as atrophic or ulcerated lesions, intermingled with white striae and plaques. Rare forms are associated with formation of bullae. According to clinical presentation, OLP has been classified into white (also described as keratotic or reticular/plaque like forms) or red lesions (also described as atrophic/erosive) (1-4). White forms are usually asymptomatic, but red lesions often result in pain or a burning sensation with significant discomfort to the patient (1-4).

Histologically, OLP is characterized by the presence of a distinct band-like zone of lymphocytic infiltration that is confined to the superficial (juxta-epithelial) aspect of the connective tissue, accompanied by epithelial alterations such as degeneration, necrosis, and apoptosis of basal cells (1-4). In the white form of OLP, the overlying epithelium responds to immunological aggression with hyperkeratosis, while atrophy or ulceration results in the red lesions. Epithelial dysplasia is not expected and, in fact, it has been advocated that lesions with histopathological features of OLP that present epithelial dysplasia should be considered as pathological entities distinct from OLP (1-4).

Oral lichenoid lesion (OLL) is another common immune-mediated disease of the oral mucosa (1-4). It shares the clinical presentation of OLP, with striae, plaques, and eventual epithelial atrophy or ulcer (1-4). In most cases, there is an exposition to a precipitating factor such as medications or dental materials. Single or unilateral lesions, and deep perivascular or mixed infiltrate of inflammatory cells are also typical, but not always present, in OLL cases (1-4). The distinction between OLP and OLL is often a dilemma for clinicians and pathologists. Besides, the precise etiopathogenesis of OLP and OLL are still unknown.

Metallothionein (MT) is a family of four non-enzymatic proteins that provide an intracellular reservoir for zinc, protect cells from toxic heavy metals and oxidative stress, and participate in the regulation of cellular proliferation and differentiation (5-9). Also, MT influences the immune response, probably with chemotactic or regulatory/suppressive roles (5-10).

Allon et al. described MT expression in the lowest layers of the oral epithelium and in the inflammatory infiltrate of OLP-affected patients (11). Higher MT expression has been observed in hyperkeratotic (white) rather than in atrophic/erosive (red) lesions of OLP, presumably due to the more pronounced anti-apoptotic response in reticular forms of the disease (11). In contrast, amalgam, which is one of the most frequent precipitating factors for OLL, can stimulate MT expression (12). However, no other previous study has investigated the expression of this protein in OLL, or directly compared MT levels in OLP and OLL. Taken into account these paucities, the aim of this study was to explore the immunohistochemical reactivity for MT in OLP and OLL, to improve our understanding of the pathogenesis of these diseases and to determine whether MT can serve as a differential diagnostic between OLP and OLL.

Material and Methods
-Patients
This study was approved by the Institutional Committee for Ethics on Research. Forty cases of OLP and twenty OLL associated to amalgam dental fillings were reviewed following Van der Meij and Van der Waal diagnostic criteria (4). Furthermore, cases of OLP were then segregated into two distinct groups according to the clinical presentation of the disease as proposed by Ismail et al. (3): reticular and hyperplastic forms, were called white OLP, n=24; and atrophic and erosive forms, were called red OLP, n=16. Data concerning age, gender, ethnicity, primary site, number of lesions, symptoms and symptom duration was retrieved from dental files.

-Immunohistochemical data
Immunohistochemical assays were performed on 3mm thick tissue sections using the streptavidin-biotin-peroxidase method according to standard protocols. After deparaffinization and hydration, sections were subjected to antigen retrieval using EDTA+Tween 20 buffer (pH=8.0) in a decloaking chamber (Biocare Medical, Concord, CA, USA) for 15 minutes at 110°C. Endogenous avidin and biotin binding activities were blocked using skim milk and white eggs. Endogenous peroxidase activity was blocked using three washes of 3% H₂O₂, each 10 minutes in duration. Incubation with a protein block solution for 15 minutes at room temperature was performed to prevent nonspecific binding (Starr Trek Universal HRP Detection System, Biocare Medical). The sections were incubated with monoclonal mouse anti-metallothionein antibody (clone E9, Dako North America Inc., Carpinteria, CA, USA) at a dilution of 1:400, in a humid chamber at 25°C for 2 hours. Signal amplification and staining were developed using the Starr Trek Universal HRP Detection System (Biocare Medical), and then the sections were counterstained with Harris hematoxylin. As a negative control, primary antibodies were replaced with phosphate-buffered saline. Samples of hepatocellular carcinomas were used as positive controls, controls based on manufacturer’s guidelines.

-Immunostaining evaluation
Evaluation of the immunohistochemical staining was
performed with an optical microscope by two investigators (G.G.M. and C.S.S.) using the Quickscore method (13). Briefly, for each epithelial layer of each case the proportion of stained (positive) epithelial cells throughout the section was scored from one to six (1: 0-4%; 2: 5%-19%; 3: 20%-39%; 4: 40%-59%; 5: 60%-79%; 6: 80%-100%). The intensity of staining was also scored from zero to three, corresponding to the presence of negative, weak, intermediate, or strong staining, respectively. The product of scores attributed to proportion and intensity of staining was the final quickscore. Quickscore were given only to distinctive areas of each sub-group. For example, in the white-OLP group only keratinized and acanthotic epithelial areas were analyzed. And, for the red-OLP, just atrophic epitheliums were examined.

-Statistical analysis
Median quickscore values between OLP and OLL, as well as between white and red OLP samples were compared with the Mann-Whitney U test. P values < 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software, version 5.01, San Diego, CA).

Results
-Clinic-pathological data
As shown in Table 1, most of the patients were white women, in their fifth decade of life. Buccal mucosa was the most frequent site of involvement. All cases of white OLP was asymptomatic, while pain or burning were reported for all cases of red OLP and in 40% of OLL. Most of OLL lesions were clinically described as white lesions, only four OLL were described as red-white mixed lesions. Representative pictures of the clinical aspect of these lesions are shown in Figure 1.

![Representative pictures of clinical aspects](image)

**Table 1:** Clinical features of the patients enrolled in the study.

| Clinical features | OLP (n = 40) | OLP White (n = 24) | OLP Red (n = 16) | OLL (n = 20) |
|-------------------|-------------|--------------------|-----------------|--------------|
| Mean age (years)  | 45.8±14.1   | 43.5±15.8          | 48.7±11.5       | 52.0±10.8    |
| Male:Female ratio | 1:3.6       | 1:3.8              | 1:2.7           | 1:3.3        |
| White:Non-white ratio | 1:0.35 | 1:0.33       | 1:0.37 | 1:0.4 |
| Main location     | Buccal mucosa (68.75%) | Buccal mucosa (75%) | Buccal mucosa (62.5%) | Buccal mucosa (50.0%) |
| Number of sites involved | 2 (52.5%); 3 or more (47.5%) | Two or more (100%) | Two or more (100%) | Only one (100%) |
| Symptoms*         | 40%         | 0%                 | 100%            | 40%          |
| Mean complaining time (months) | 13.2±18.4 | 20.6±24.7 | 6.9±8.8 | 8.6±7.2 |

*Described as pain, burning or discomfort.
Immunohistochemical data
The immunohistochemical reactivity for MT was observed as cytoplasmic and nuclear staining of varied intensity, depicting a mosaic pattern. In all groups, staining was more intense in the cells of the basal epithelial layer and was gradually less evident in upper layers. Figure 2 illustrates representative staining patterns for each group. As expected, MT reactivity was more intense in the white forms of OLP when compared to the red ones (Table 2 and Fig. 3A to 3D). Finally, lesions of OLP depicted significantly higher MT reactivity than OLL (Table 3 and Fig. 3E and 3F). There was no difference in the MT expression in white OLL and red-white mixed OLL.

Discussion
In 1978, the World Health Organization (WHO) proposed a clinical and histopathological definition for OLP to facilitate its recognition and differentiation from pre-cancerous disorders (14). This publication has been applied as the golden standard criteria for OLP diagnosis for at least 25 years. However, subsequent studies concluded that this classification has unsatisfactory inter- and intra-observer variability (4,14-18). This inconsistency may be partially explained by the difficulty in separating OLP from several other diseases such as OLL or even lupus erythematosus.

To overcome this problem, Van der Meij and Van der Waal in 2003 proposed a set of revised diagnostic criteria of OLP and OLL, including clinical as well as histopathological aspects (4). This new classification demonstrated less inter- and intra-observer variability and enable pathologist/researchers to perform more reproducible diagnosis, eliminating individual diagnostic variation (4,18). Moreover, such data could lead to better clinical, pathological and etiological characterization of these lesions, dismissing some biases related to the incorrect naming of these disorders. To guarantee more reproducible analysis, we utilized the modified WHO diagnostic criteria of OLP and OLL as proposed in 2003 (4). However, such classification has some limitations, since these proposed criteria are not universally present in all OLP and/or OLL patients.

In the present study, we observed that MT expression is mainly observed in basal and parabasal layers of the oral epithelium, as previously described (11,19,20). In 1992, Hanada and collaborators explained that reactivity for MT in cutaneous lesions of lichen planus was concentrated in the granular layer of the epidermis, in the same way of healthy skin, but was less evident in the former (10). Afterwards, van den Oord and De Ley described the distribution of MT in normal and pathological human skin (21). Although they did not include lichen planus in their analysis, the MT immunohistochemical staining was described as strongly positive in basal keratinocytes of epidermis (21). Interestingly, an MT interrupted staining was found in the basal layer of interface dermatitis (21). In 1998, Matsuura, Tsukifuji, and Shinkai described MT expression in idiopathic annular lichen planus of the skin where MT immune staining increased as well, but it was discontinuous around the rim of erythema and undetectable in the center of the lesion (19). Other authors had depicted MT positivity in lower areas of the epidermis in one case of Palmoplantar lichen planus (20).

Regarding to oral lesions, it was only in 2014 that Allon and co-workers described that epithelial MT expression was significantly higher in keratotic OLP than in atrophic and erosive forms (11). In our work, we also observed that MT expression was less evident in red than
Table 2: Median Quickscore in white OLP and red OLP groups. Range were presented inside parenthesis.

| Analysed areas | OLP-W (n=24) | OLP-R (n=16) | p value* |
|----------------|--------------|--------------|----------|
|                | Cytoplasmatic | Cytoplasmatic |          |
| General        | 2.0 (0.4-6.9) | 1.8 (0-3.8)  | 0.0992   |
| Basal layer    | 8.6 (0.5-13.8)| 7.6 (0-9.5)  | **0.0467**|
| Parabasal layer| 2.1 (0-6.6)  | 1.0 (0-3.7)  | 0.0159   |
| Spinous layer  | 0.0 (0-2.2)  | 0.0 (0-0.3)  | 0.1418   |
| Keratin layer  | 0.0 (0-0.20) | 0.0 (0-0.4)  | 0.6309   |

| Analysed areas | OLP-W (n=24) | OLP-R (n=16) | p value* |
|----------------|--------------|--------------|----------|
|                | Nucleous     | Nucleous     |          |
| General        | 1.8 (0.1-7.1)| 1.8 (0-3.6)  | 0.3774   |
| Basal layer    | 8.6 (0.3-17.4)| 8.3 (0-13.8)| 0.3702   |
| Parabasal layer| 1.5 (0-7.4)  | 0.49 (0-4.1) | **0.0129**|
| Spinous layer  | 0.0 (0-1.1)  | 0.0 (0-0.2)  | **0.0492**|
| Keratin layer  | 0.0 (0-0)    | 0.0 (0-0)    | -        |

*Mann Whitney test; OLP-R: oral lichen planus - red forms; OLP-W: oral lichen planus - white forms.

white lesions of OLP. These results suggest that MT expression is related to the inflammatory pathogenesis of OLP. In addition, these findings validate our technique, since we were able to reproduce someone else’s data (11).

A previous manuscript has described the MT immunolocalization on amalgam tattoos specimens (12). This paper portrayed that a weak MT positivity was usually seen in inflammatory and endothelial cells close related with amalgam particles (12). The authors affirm the presence of MT immunopositivity in the basal cell layer of the mucosa epithelium in all studied samples (12). Furthermore, MT-staining appears to be stronger in the epithelial basement areas impregnated with powdered amalgam particles (12). Such data reinforces our findings, since we could also evidence a very similar MT immunopositivity in the basal cell layer of OLP and OLL samples. Taken these files together, we could assume that MT expression is always upper-regulated to protect mucosal keratinocytes from variable sources of cellular stress.

Previous studies have classified OLL in four major types based on the method of instigation: oral lichenoid lesions associated with amalgam restorations; oral lichenoid drug reactions; lichenoid lesions in chronic graft-versus-host disease, and lesions that lack an evident triggering agent but have a lichen planus like aspect except for one or more clinical features (1-4,22,23). In these lines, OLL can only be distinguished from OLP by two main features: 1- association with the administration of a drug, contact with a metal (such as dental restorations), foodstuff or systemic disease; and 2- the resolution of the lesions when the causative agent is removed (1-4,22,23). In attempt to facilitate such seg-
Table 3: Median Quickscore in OLP and OLL groups. Range were presented inside parenthesis.

| Analysed areas | OLP (n=40) | OLL (n=20) | p value* |
|----------------|------------|------------|----------|
|                | Cytoplasmatic | Cytoplasmatic |          |
| General        | 1.9 (0-6.9) | 1.4 (0-3.5) | 0.0816   |
| Basal layer    | 8.0 (0-13.8) | 4.3 (0-12.6) | **0.0019** |
| Parabasal layer| 1.45 (0-6.6) | 1.7 (0-9.4) | 0.8366   |
| Spinous layer  | 0.0 (0-2.2) | 0.0 (0-6.0) | 0.2408   |
| Keratin layer  | 0.0 (0-0.4) | 0.0 (0-0.2) | 0.5894   |

| Analysed areas | OLP (n=40) | OLL (n=20) | p value* |
|----------------|------------|------------|----------|
|                | Nucleous   | Nucleous   |          |
| General        | 1.8 (0-7.1) | 1.3 (0-5.3) | 0.1238   |
| Basal layer    | 8.3 (0-17.4) | 3.4 (0-12.6) | **0.0011** |
| Parabasal layer| 1.2 (0-7.4) | 1.1 (0-7.2) | 0.7348   |
| Spinous layer  | 0.0 (0-1.1) | 0.0 (0-6.0) | 0.0781   |
| Keratin layer  | 0.0 (0-0)    | 0.0 (0-0) | -        |

*Mann Whitney test; OLP (R): oral lichen planus - red forms; OLL: oral lichenoid lesion

As cited above, many clinical, histopathological, immunological and genetic criteria for differentiating OLP and OLL has been proposed in literature; however, there is currently no established cutoff to facilitate their segregation (1-4,22-27). Furthermore, since most of the described information relies on observational studies, such data must be taken with care because of inherent biases. Since there are few studies involving markers that facilitate the differential diagnosis between the OLP and OLL cases, prospective studies with stronger evidence levels are still needed to better understand the pathogenesis and the trustworthy segregational markers of these lesions.

In conclusion, the presented results show that differences in MT expression were linked with OLP and OLL etiopathogenesis and clinical appearance. Our data could not support any further clinical implications for the use of MT as a tool in the diagnosis and management of these lesions. Further studies are still necessary to elucidate this topic. In the future, prospective blind controlled trials will answer if MT immune tagging has a real potential to be an OLP diagnosis marker, with prognostic value.

References
1. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:e1-12.
2. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46:207-14.
3. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49:89-106.
Metallothionein expression in oral lichen planus and lichenoid lesions

4. van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32:507-12.

5. Thirumooorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M, Ganesh G, Chatterjee M. A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol. 2011;9:54. doi: 10.1186/1477-7819-9-54.

6. Gumulec J, Raudenska M, Adam V, Kizek R, Masarik M. Metallothionein - immunohistochemical cancer biomarker: a meta-analysis. PLoS One. 2014;9:e85346.

7. Lynes MA, Hidalgo J, Manso Y, Devischer L, Laukens D, Lawrence DA. Metallothionein and stress combine to affect multiple organ systems. Cell Stress Chaperones. 2014;19:605-11.

8. Devischer L, Hindryckx P, Lynes MA, Waeytens A, Cuvelier C, De Vos F, et al. Role of metallothioneins as danger signals in the pathogenesis of colitis. J Pathol. 2014;233:89-100.

9. Haase H, Rink L. Zinc signals and immune function. Biofactors. 2014;40:27-40.

10. Hanada K, Baba T, Hashimoto I, Fukui R, Watanabe S. Possible role of cutaneous metallothionein in protection against photo-oxidative stress--epidermal localization and scavenging activity for superoxide and hydroxyl radicals. Photodermatol Photoimmunol Photomed. 1992-1993;9:209-13.

11. Allon I, Ofir M, Vered H, Hirshberg A. Metallothionein, a marker of antipapostasis, is associated with clinical forms of oral lichen planus. J Oral Pathol Med. 2014;43:728-33.

12. Leite CM, Botelho AS, Oliveira JR, Cardoso SV, Loyola AM, Gomez RS, et al. Immunolocalization of HLA-DR and metallothionein on amalgam tattoos. Braz Dent J. 2004;15:99-103.

13. Dettre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876-8.

14. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46:518-39.

15. Onofre MA, Sposto MR, Navarro CM, Motta ME, Turatti E, Almeida RT. Potentially malignant epithelial oral lesions: discrepancies between clinical and histological diagnosis. Oral Dis. 1997;3:148-52.

16. van der Meij EH, Reibel J, Slotower PJ, van der Wal JE, de Jong WF, van der Waal I. Interobserver and intraobserver variability in the histologic assessment of oral lichen planus. J Oral Pathol Med. 1999;28:274-7.

17. van der Meij EH, Scheepman KP, Plonait DR, Axéll T, van der Waal I. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med. 2002;31:95-8.

18. Rad M, Hashemipoor MA, Mojtahedi A, Zarei MR, Chamani G, Kakoee S, et al. Correlation between clinical and histopathologic diagnoses of oral lichen planus based on modified WHO diagnostic criteria. Oral Surg Oral Med Oral Radiol Endod. 2009;107:796-800.

19. Matsuura C, Tsukifuri R, Shinkai H. Annular lichen planus showing a change in metallothionein expression on immunohistochemistry. Br J Dermatol. 1998;138:1043-5.

20. Abreu Velez AM, Howard MS, Pereyo N. Palmar and plantar lichen planus: a case report and review of the literature. An Bras Dermatol. 2015;90:175-7.

21. van den Oord JJ, De Ley M. Distribution of metallothionein in normal and pathological human skin. Arch Dermatol Res. 1994;286:62-8.

22. Casparis S, Borm JM, Tektas S, Kamarachev J, Locher MC, Damrau G, et al. Oral lichen planus (OLP), oral lichenoid lesions (OLL), oral dysplasia, and oral cancer: retrospective analysis of clinicopathological data from 2002-2011. Oral Maxillofac Surg. 2015;19:149-56.

23. Jahanshahi G, Ghalayani P, Maleki L. Mast cells distribution and variations in epithelium thickness and basement membrane in oral lichen planus lesion and oral lichenoid reaction. Dent Res J (Isfahan). 2012;9:180-4.

24. Reddy DS, Sivapathasundaram B, Saraswathi TR, SriRam G. Evaluation of mast cells, eosinophils, blood capillaries in oral lichen planus and oral lichenoid mucositis. Indian J Dent Res. 2012;23:695-6.

25. Arreaza AJ, Rivera H, Correnti M. Expression of COX-2 and bel-2 in oral lichen planus lesions and lichenoid reactions. Eacncrmedicscience. 2014;8:411.

26. Batu Ş, O˘fuo˘glu D, Ergun S, Warnakulasuriya S, Uslu E, Güven Y, et al. Evaluation of prolidase activity and oxidative stress in patients with oral lichen planus and oral lichenoid contact reactions. J Oral Pathol Med. 2016;45:281-8.

27. Rodrigues LN, Sousa SF, Silva R, Abreu M, Pires FR, Mesquita RA, et al. Allelic loss in amalgam-associated oral lichenoid lesions compared to oral lichen planus and mucosa. Oral Dis. 2017;23:471-6.

Acknowledgements
This work was supported by research grants from the Brazilian Council for Research and Development (CNPq), the National Coordination of Post-Graduated Personnel (APES), and the Minas Gerais State Foundation for Research Support (FAPEMIG).

The authors would like to thank Dr. Sarah Bondos for kindly revising the stylistic and grammar of this manuscript.

Conflicts of interest
All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of financial conflicts include employment, consultancies, stock ownership, honoraria, paid expert testimony, patents or patent applications, and travel grants, all within 3 years of beginning the work submitted.